Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
Michael R. Migden, Sunandana Chandra, Guilherme Rabinowits, et al.
Future Oncology (2020) Vol. 16, Iss. 4, pp. 11-19
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Feng Ye, Saikat Dewanjee, Yuehua Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 267
Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 59
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma
Alessia Villani, Luca Potestio, Gabriella Fabbrocini, et al.
Advances in Therapy (2022) Vol. 39, Iss. 3, pp. 1164-1178
Open Access | Times Cited: 53
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
Alexander J. Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (2023) Vol. 193, pp. 113252-113252
Open Access | Times Cited: 34
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
Martin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
European Journal of Cancer (2020) Vol. 138, pp. 125-132
Closed Access | Times Cited: 57
Formulation and Characterization of Metformin-Loaded Ethosomes for Topical Application to Experimentally Induced Skin Cancer in Mice
Ibrahim A. Mousa, Taha M. Hammady, Shadeed Gad, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 6, pp. 657-657
Open Access | Times Cited: 37
Cancer Immunotherapy and Delivery System: An Update
Ming Yang, Olamide Tosin Olaoba, Chunye Zhang, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1630-1630
Open Access | Times Cited: 30
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma
Alessia Villani, Sonia Sofía Ocampo‐Garza, Luca Potestio, et al.
Expert Opinion on Drug Safety (2021) Vol. 21, Iss. 1, pp. 21-29
Closed Access | Times Cited: 28
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
Jakub Wesolowski, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak
Cancers (2022) Vol. 14, Iss. 16, pp. 3860-3860
Open Access | Times Cited: 21
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation
Luca Potestio, Massimiliano Scalvenzi, Aimilios Lallas, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1732-1732
Open Access | Times Cited: 4
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma
Soo Jung Park, David M. Ellison, Ryan Weight, et al.
Future Oncology (2025), pp. 1-6
Open Access
Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
Layna Mager, Samantha Gardeen, David R. Carr, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2135-2142
Open Access | Times Cited: 10
An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma
James P. Pham, Ramon Staeger, Anthony M. Joshua, et al.
European Journal of Cancer (2024) Vol. 214, pp. 115121-115121
Open Access | Times Cited: 3
Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals
Dae Young Lee, Eunji Im, Dahye Yoon, et al.
Seminars in Cancer Biology (2020) Vol. 86, pp. 1033-1057
Closed Access | Times Cited: 25
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Gerasimos Konidaris, E. Paul, Andreas Kuznik, et al.
Value in Health (2021) Vol. 24, Iss. 3, pp. 377-387
Open Access | Times Cited: 23
Updates in Skin Cancer in Transplant Recipients and Immunosuppressed Patients: Review of the 2022–2023 Scientific Symposium of the International Immunosuppression and Transplant Skin Cancer Collaborative
Catherine Pisano, Justin J. Leitenberger, Melissa Pugliano‐Mauro, et al.
Transplant International (2024) Vol. 37
Open Access | Times Cited: 2
Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
Dáire Goodman
JPRAS Open (2022) Vol. 33, pp. 155-160
Open Access | Times Cited: 12
Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
Nerina Denaro, Emanuela Passoni, Alice Indini, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1500-1500
Open Access | Times Cited: 4
Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices
Wenzhen Ge, Ning Wu, Chieh-I Chen, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 841-854
Open Access | Times Cited: 1
New Developments in the Management of Cutaneous Squamous Cell Carcinoma
Thomas Knackstedt, Rebecca Knackstedt, Michelle Djohan, et al.
Plastic & Reconstructive Surgery (2021) Vol. 147, Iss. 3, pp. 492-504
Closed Access | Times Cited: 10
A structured review of quality of life in advanced and high‐risk cutaneous squamous cell carcinoma shows the need for more studies and better measures
Rachel Starkings, Valerie Shilling, Valerie Jenkins, et al.
Skin Health and Disease (2021) Vol. 1, Iss. 3
Open Access | Times Cited: 9
FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment
Mizuki Tagami, Anna Kakehashi, Atsuko Katsuyama-Yoshikawa, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0263895-e0263895
Open Access | Times Cited: 6
Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel
Eve Lebas, Nathalie Marchal, Andrée Rorive, et al.
Expert Review of Anticancer Therapy (2021) Vol. 21, Iss. 4, pp. 355-363
Closed Access | Times Cited: 8
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
Maximilian Haist, Henner Stege, Berenice M. Lang, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5543-5543
Open Access | Times Cited: 5
Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
Marta Pabianek, Aleksandra Lesiak, Dariusz Nejc, et al.
Current Oncology (2022) Vol. 29, Iss. 10, pp. 7794-7801
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top